13F 申报指南13F 概念全攻略
什么是 SEC Form 13F 申报？美股机构大户持股全攻略
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
AlphaSMO 权威研究指南阅读专题
CIK: 0001389933
申报总市值
US$5.2亿
US$5.2亿
76 檔
25.0%
截至 Q2 2025 季度末，DAFNA Capital Management LLC 的美股持仓估值约为 US$5.2亿，全数申报仓位共有 76 档。
在 Q2 2025，DAFNA Capital Management LLC 展现出较为审慎的避险与获利了结姿态。本季共减仓 21 个仓位并完全清仓 10 档持股，调降曝光的仓位数量高于加仓动作。
在资产配置集中度方面，DAFNA Capital Management LLC 的前 5 大核心持股（包含 XBI, STXS, RVMD 等）合计占整体申报市值的 25.0%，反映机构在主要关键仓位上的权重分布。
| # | 代码 | 标的名称 | 资产子类别 | 占比 | 占比变动 | 持仓量变化 | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-科技型 | 9.51% | -3.32% | +2.72% | |
| 2 | STXS | Stereotaxis Inc | 股票-其他 | 8.01% | -1.24% | — | |
| 3 | RVMD | Revolution Medicines Inc | 股票-医疗保健 | 6.88% | +7.24% | +3.20% | |
| 4 | 2655787D | Blueprint Medicines CORP | 股票-其他 | 5.97% | — | +10.84% | |
| 5 | ✓ | Merus N V | 股票-其他 | 5.79% | — | -13.64% | |
| 6 | ATRC | Atricure Inc | 股票-其他 | 5.36% | -0.69% | — | |
| 7 | CYTK | Cytokinetics Inc | 股票-医疗保健 | 3.63% | -0.47% | — | |
| 8 | IDYA | Ideaya Biosciences Inc | 股票-其他 | 3.59% | -0.08% | +5.05% | |
| 9 | IBB | Ishares Biotechnology ETF | ETF-科技型 | 3.58% | -0.85% | — | |
| 10 | ASND | Ascendis Pharma A/S | 股票-其他 | 3.46% | -1.21% | EXIT | |
| 11 | XENE | Xenon Pharmaceuticals Inc | 股票-其他 | 2.49% | -0.43% | +5.19% | |
| 12 | NBIX | Neurocrine Biosciences Inc | 股票-医疗保健 | 2.45% | -0.26% | -1.40% | |
| 13 | AXGN | Axogen Inc | 股票-其他 | 2.22% | -0.04% | +8.96% | |
| 14 | 4XC1 | Kalvista Pharmaceuticals Inc | 股票-其他 | 1.82% | -1.22% | EXIT | |
| 15 | DXCM | Dexcom Inc | 股票-医疗保健 | 1.58% | -0.12% | — | |
| 16 | DAWNGBX | Day One Biopharmaceuticals I | 股票-其他 | 1.58% | -4.77% | EXIT | |
| 17 | STOK | Stoke Therapeutics Inc | 股票-其他 | 1.57% | -0.15% | +13.06% | |
| 18 | TNDM | Tandem Diabetes Care Inc | 股票-其他 | 1.51% | -0.53% | — | |
| 19 | RCUS | Arcus Biosciences Inc | 股票-其他 | 1.41% | +0.42% | +0.40% | |
| 20 | SNDX | Syndax Pharmaceuticals Inc | 股票-其他 | 1.41% | +0.24% | -0.17% | |
| 21 | MLYS | Mineralys Therapeutics Inc | 股票-其他 | 1.39% | -0.01% | +20.16% | |
| 22 | ASND 2.25 04-01-28债券 | Ascendis Pharma A/s | 债券 | 1.38% | -1.35% | EXIT | |
| 23 | URGN | UroGen Pharma Ltd. | 股票-其他 | 1.32% | — | -29.03% | |
| 24 | INGN | Inogen Inc | 股票-其他 | 1.18% | -0.15% | +32.21% | |
| 25 | LKFT | Lakefront Biotherapeutic-adr | 股票-其他 | 1.01% | -0.15% | — | |
| 26 | BHVN | Biohaven Ltd. | 股票-其他 | 0.92% | -1.24% | +6.81% | |
| 27 | ✓ | Proqr Therapeutics N.v. | 股票-其他 | 0.88% | -0.04% | — | |
| 28 | EWTX | Edgewise Therapeutics Inc | 股票-其他 | 0.86% | +0.96% | +30.03% | |
| 29 | PODD | Insulet CORP | 股票-医疗保健 | 0.86% | +1.28% | -16.81% | |
| 30 | IMVT | Immunovant Inc | 股票-其他 | 0.85% | +0.25% | +12.65% | |
| 31 | ALKS | Alkermes plc | 股票-医疗保健 | 0.82% | -0.11% | +10.14% | |
| 32 | BCAX | Bicara Therapeutics Inc | 股票-其他 | 0.81% | -0.30% | +49.53% | |
| 33 | TELA | Tela Bio Inc | 股票-其他 | 0.77% | +0.01% | — | |
| 34 | KURA | Kura Oncology Inc | 股票-其他 | 0.74% | -0.19% | — | |
| 35 | DNLI | Denali Therapeutics Inc | 股票-其他 | 0.65% | +2.23% | +31.74% | |
| 36 | CMPS | Compass Pathways PLC | 股票-其他 | 0.63% | +2.39% | +14.06% | |
| 37 | ALGN | Align Technology Inc | 股票-医疗保健 | 0.57% | -0.13% | — | |
| 38 | BCRX | Biocryst Pharmaceuticals Inc | 股票-其他 | 0.54% | -0.17% | -60.90% | |
| 39 | CATBUSD | Astria Therapeutics Inc | 股票-其他 | 0.48% | — | +3.18% | |
| 40 | KROS | Keros Therapeutics Inc | 股票-其他 | 0.48% | — | — | |
| 41 | VKTX | Viking Therapeutics Inc | 股票-医疗保健 | 0.47% | — | — | |
| 42 | ARAY | Accuray Inc | 股票-其他 | 0.46% | -0.07% | — | |
| 43 | BWAY | Brainsway Ltd-adr | 股票-其他 | 0.46% | — | -18.77% | |
| 44 | ALLO | Allogene Therapeutics Inc | 股票-其他 | 0.43% | +0.03% | — | |
| 45 | LXEO | Lexeo Therapeutics Inc | 股票-其他 | 0.42% | -0.16% | — | |
| 46 | FHTX | Foghorn Therapeutics Inc | 股票-其他 | 0.39% | -0.02% | -1.41% | |
| 47 | 2662247D | Iteos Therapeutics Inc | 股票-其他 | 0.39% | — | -33.98% | |
| 48 | ORIC | Oric Pharmaceuticals Inc | 股票-其他 | 0.38% | -0.22% | EXIT | |
| 49 | CMPX | Compass Therapeutics Inc | 股票-其他 | 0.38% | — | — | |
| 50 | ✓ | Immatics NV | 股票-其他 | 0.36% | -0.28% | — |
| # | 代码 | 标的名称 | 占比变动 | 持仓量变化 | 异动类型 |
|---|---|---|---|---|---|
| 1 | 2655787D | Blueprint Medicines CORP | +2.2% | +10.84% | 加仓 |
| 2 | STXS | Stereotaxis Inc | +1.2% | — | 不变 |
| 3 | IDYA | Ideaya Biosciences Inc | +0.9% | +5.05% | 加仓 |
| 4 | STOK | Stoke Therapeutics Inc | +0.7% | +13.06% | 加仓 |
| 5 | CMPX | Compass Therapeutics Inc | +0.4% | NEW | 新建仓 |
| 6 | DXCM | Dexcom Inc | +0.3% | — | 不变 |
| 7 | RVMD | Revolution Medicines Inc | +0.3% | +3.20% | 加仓 |
| 8 | ✓ | Proqr Therapeutics N.v. | +0.3% | — | 不变 |
| 9 | ✓ | Merus N V | +0.3% | -13.64% | 减仓 |
| 10 | TELA | Tela Bio Inc | +0.3% | — | 不变 |
| 11 | BDTX | Black Diamond Therapeutics I | +0.3% | +236.43% | 加仓 |
| 12 | INGN | Inogen Inc | +0.3% | +32.21% | 加仓 |
| 13 | XBI | Ss Spdr S&p Biotech ETF | +0.2% | +2.72% | 加仓 |
| 14 | NBIX | Neurocrine Biosciences Inc | +0.2% | -1.40% | 减仓 |
| 15 | DNLI | Denali Therapeutics Inc | +0.2% | +31.74% | 加仓 |
| 16 | KROS | Keros Therapeutics Inc | +0.1% | — | 不变 |
| 17 | LKFT | Lakefront Biotherapeutic-adr | +0.1% | — | 不变 |
| 18 | ALGN | Align Technology Inc | +0.1% | — | 不变 |
| 19 | FHTX | Foghorn Therapeutics Inc | +0.1% | -1.41% | 减仓 |
| 20 | LRMR | Larimar Therapeutics Inc | +0.1% | — | 不变 |
| 21 | NKTR | Nektar Therapeutics | +0.1% | NEW | 新建仓 |
| 22 | ✓ | Mediwound LTD | +0.1% | — | 不变 |
| 23 | CMPS | Compass Pathways PLC | +0.1% | +14.06% | 加仓 |
| 24 | ✓ | Immatics NV | +0.1% | — | 不变 |
| 25 | LXEO | Lexeo Therapeutics Inc | +0.1% | — | 不变 |
| 26 | GPCR | Structure Therapeutics Inc | +0.1% | — | 不变 |
| 27 | PRCT | Procept Biorobotics CORP | +0.1% | NEW | 新建仓 |
| 28 | ASND 2.25 04-01-28债券 | Ascendis Pharma A/s | 0% | — | 不变 |
| 29 | BWAY | Brainsway Ltd-adr | 0% | -18.77% | 减仓 |
| 30 | NGNE | Neurogene Inc | 0% | -0.78% | 减仓 |
| 31 | BCAX | Bicara Therapeutics Inc | 0% | +49.53% | 加仓 |
| 32 | IMVT | Immunovant Inc | 0% | +12.65% | 加仓 |
| 33 | ALEC | Alector Inc | 0% | — | 不变 |
| 34 | VKTX | Viking Therapeutics Inc | 0% | — | 不变 |
| 35 | IPSC | Century Therapeutics Inc | 0% | — | 不变 |
| 36 | 2662247D | Iteos Therapeutics Inc | 0% | -33.98% | 减仓 |
| 37 | RCUS | Arcus Biosciences Inc | 0% | +0.40% | 加仓 |
| 38 | ✓ | Compugen LTD | 0% | — | 不变 |
| 39 | AUTL | Autolus Therapeutics PLC | 0% | -27.45% | 减仓 |
| 40 | AQST | Aquestive Therapeutics Inc | 0% | — | 不变 |
| 41 | GOSS | Gossamer Bio Inc | 0% | -6.38% | 减仓 |
| 42 | VYNE | Vyne Therapeutics Inc | 0% | — | 不变 |
| 43 | STRO | Sutro Biopharma, Inc. | 0% | — | 不变 |
| 44 | MLYS | Mineralys Therapeutics Inc | — | +20.16% | 加仓 |
| 45 | CATBUSD | Astria Therapeutics Inc | — | +3.18% | 加仓 |
| 46 | ORIC | Oric Pharmaceuticals Inc | — | -44.10% | 减仓 |
| 47 | ✓ | Adc Therapeutics SA | — | -45.52% | 减仓 |
| 48 | ✓ | 0% | — | 不变 | |
| 49 | TNYA | Tenaya Therapeutics Inc | 0% | EXIT | 清仓 |
| 50 | ERAS | Erasca Inc | 0% | +2.94% | 加仓 |
根据 SEC 官方 Form 13F 申报备案，DAFNA Capital Management LLC 在 Q2 2025 季度的美股持仓总市值约为 US$5.2亿，共申报了 76 个公开持股仓位。
在 Q2 2025 季度，DAFNA Capital Management LLC 按市值排列的前三大核心持股分别为：XBI (9.5%)、STXS (8.0%)、RVMD (6.9%)。其中最大持股仓位 XBI 占据整体投资组合约 9.5% 的权重。
精选 AlphaSMO 大户持股与内部人交易深度分析，提升投资决策胜率
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
本季最大新建仓标的
CMPX
市值: US$136.9万
本季最大获利了结 / 清仓标的
TSVT*
前期市值: US$212.1万
在 Q2 2025 季度中，DAFNA Capital Management LLC 共进行了 56 项持仓异动，包含新建仓 3 个仓位、加仓 22 个仓位、减仓 21 个仓位以及清仓 10 个仓位。 其中最大新建仓标的为 CMPX。 本季清仓仓位包含 TSVT*。
本页面所有持股数据均直接同步自美国证券交易委员会（SEC）EDGAR 官方系统之 13F-HR / 13F-HR/A 季度申报文件。AlphaSMO 通过机器解析 CUSIP 与个股对照，提供 100% 精准对齐的历史时序数据集，并支持 Schema.org 结构化数据格式。
解析公司高管、董事与 10% 大股东之 Form 4 内部人交易申报，掌握高管自家股票买卖第一手信号。
深入剖析 5% 股权申报门槛、13D 与 13G 之差异，以及最新 SEC 申报时程规范，洞察机构法人的激进投资动向。